Fig. 1 · Structure

Documents & Downloads

Carmofur

Cat. No. A10183 CAS 61422-45-5
Carmofur is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Carmofur inhibits acid ceramidase (AC). A recombinant rat AC assay reported an IC50 of 29 ± 5 nM. Human AC crystallography identified a carmofur-derived moiety covalently linked to catalytic Cys143. The rat assay also showed partial recovery after dialysis; these findings do not establish identical inhibition kinetics across species or assay conditions. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Acid ceramidase

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.029 μM Inhibition of rat recombinant acid ceramidase expressed in human HEK293 cells using N-lauroylceramide as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC/MS analysis [PMID: 23614460]
HEK293 IC50 20.7 nM Inhibition of human C-terminal His-tagged acid ceramidase variant 1 expressed in HEK293 cells using fluorogenic substrate Rbm-14-12 preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorogenic assay [PMID: 28603987]

Carmofur Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Carmofur from 3 published references. In vitro models include recombinant rat acid ceramidase. In vivo models include twitcher mice and Twi/FDH mice.

Carmofur In Vitro Studies

In SW403 and LNCaP cells, carmofur reduced AC activity and increased selected ceramide species. Separate 5-FU treatment did not reproduce the short-term lipid response. These experiments establish cellular pharmacodynamic effects in the tested models. [1]

In fibroblasts from one Krabbe patient, 3 µM carmofur for two weeks decreased psychosine and increased ceramides relative to vehicle. Replicate cultures from one donor do not establish a response across patients. [3]

Rat acid ceramidase inhibition and kinetic characterization

Biochemical assay · Recombinant rat acid ceramidase [1]

Carmofur inhibited AC; 5-FU was much weaker. Reduced maximal velocity, time-dependent onset and partial recovery after dialysis qualify the inhibition mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AC inhibitionIC50 29 ± 5 nM (mean ± s.e.m.; Results n = 4; Table 1 describes 3 determinations; Fig. 1 describes n = 3).[1]
5-FU inhibition of rat ACIC50 >1 mM[1]
Onset and recovery of AC inhibitionQualitative Time-dependent inhibition; significant but incomplete reversal after 12-h dialysis.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response; kinetic comparisons at 20 and 60 nM; dialysis experiment at 200 nM.
Exposure duration
Activity reaction: 30 min; preincubation varied in Fig. 1C; dialysis: 12 h.
Method
LC/MS quantification of lauric acid released from N-lauroyl ceramide; pH 4.5, 37 °C.
Vehicle
DMSO 1% in kinetic comparison (Fig. 1B).
Co-treatment
None; comparator treatments are separate controls.
Reported limits
A single preincubation time for the potency fit is not specified in the read assay description; do not transfer the time-course peak to that fit.
Methods and source locations

Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur

Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.

Results: Carmofur is a highly potent AC inhibitor; Fig. 1A–D; Tables 1–2; SI Acid Ceramidase Activity

AC inhibition: LC/MS enzyme assay; value printed in text/table, not estimated from curve. — Results first paragraph; Table 1; Fig. 1A caption

5-FU inhibition of rat AC: Separate comparator in the same enzyme assay. — Results first paragraph; Fig. 1A

Onset and recovery of AC inhibition: Preincubation time course and overnight dialysis with vehicle controls. — Results first paragraph; Fig. 1C–D

Cellular AC inhibition and ceramide accumulation

Cell-based study · Human SW403 colon adenocarcinoma and LNCaP prostate adenocarcinoma cells [1]

Carmofur lowered cellular AC activity and increased ceramide species in these models. Separate 5-FU treatment did not reproduce the short-term AC/ceramide response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular AC activityQualitative Concentration- and time-dependent reduction; mean ± s.e.m., n = 3–6, each assay in duplicate (caption).[1]
Cellular ceramide speciesQualitative C14:0 and C16:0 ceramides increased under the reported conditions; 5-FU did not reproduce these changes.[1]

Literature-Reported Treatment Conditions

Treatment concentration
SW403: 0.3–10 µM; LNCaP graphic: 0.3–3 µM for AC concentration response; 3 µM in time-course/lipid experiments; separate 5-FU 3 µM.
Exposure duration
3 h for concentration response; 20 min–6 h AC time course; 1, 3 and 6 h shown for ceramides.
Method
Drug treatment of intact cells; AC activity in lysates by LC/MS and cellular ceramides by LC/MS.
Vehicle
0.1% DMSO; vehicle and separate 5-FU controls.
Co-treatment
None; comparator treatments are separate controls.
Reported limits
Main Fig. 2 caption gives a general 0.3–10 µM range, while LNCaP panel D displays through 3 µM. Caption describes 3-h lipid treatment but panels also show 1 and 6 h; retain panel-specific scope.
Methods and source locations

Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur

Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.

Fig. 2A–F and caption; Results first section; SI Tables S1–S2 and AC/lipid methods

Cellular AC activity: Activity measured in lysates after intact-cell treatment; vehicle and 5-FU controls. — Fig. 2A–B, D–E and caption

Cellular ceramide species: LC/MS; no exact bar-derived concentrations adopted. — Fig. 2C,F; SI Tables S1–S2

Human AC structure with a carmofur-derived covalent adduct

Biochemical assay · Recombinant mature human acid ceramidase; X-ray crystal structure, PDB 6MHM [2]

The observed carmofur-derived moiety is covalently linked to catalytic Cys143 and occupies a hydrophobic region of the substrate-binding pocket.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Covalent modification of human ACStructural observation Continuous electron density links the carmofur-derived moiety to Cys143 Sγ.[2]
Diffraction resolutionResolution 50.00–2.74 Å; narrative rounds to 2.7 Å.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM carmofur in complex-formation mixture (structural preparation, not an IC50).
Method
X-ray crystallography and molecular replacement with activated apo-AC (5U7Z) as search model; electron-density interpretation.
Vehicle
DMSO stock and aqueous Triton X-100 used for complex formation; final DMSO fraction not specified in read text.
Co-treatment
None; comparator treatments are separate controls.
Reported limits
Complex-formation incubation time not specified in read text. This is structural evidence, not a new potency or cellular efficacy determination.
Methods and source locations

Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur

Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.

Results: Overall structure and Inhibitor binding; Table 1; Fig. 2A–B; Experimental Section: complex formation and structure determination

Covalent modification of human AC: Original Fig. 2 viewed; density shown at 1σ. — Inhibitor binding; Fig. 2A–B and caption

Diffraction resolution: X-ray crystallography; Table 1 read directly from retained HTML. — Table 1: data collection resolution range

Lipid response in Krabbe patient fibroblasts

Cell-based study · Primary human fibroblasts GM04517 from one 8-month-old Krabbe patient; homozygous GALC exons 11–17 deletion [3]

Carmofur decreased psychosine and increased ceramides compared with vehicle in this single-donor cell model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Psychosine and ceramide abundanceRelative lipid levels Psychosine decreased (P ≤ 0.05); ceramides increased (P ≤ 0.01); six biological replicates per condition.[3]

Literature-Reported Treatment Conditions

Treatment concentration
3 µM
Exposure duration
2 weeks; fresh drug/vehicle with daily complete medium replacement.
Method
Cell treatment followed by mass-spectrometric psychosine and ceramide measurement.
Vehicle
DMSO control; final percentage not specified in read paragraph.
Co-treatment
None; comparator treatments are separate controls.
Reported limits
One donor; six biological replicates per condition are cultures, not six patients.
Methods and source locations

Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur

Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.

Fig. 5B–C and caption; Mouse and Human Fibroblast Manipulations (human treatment paragraph); Mass Spectrometry; Statistical Analysis

Psychosine and ceramide abundance: Mass spectrometry; mean ± 1 SEM in general statistics; symbol thresholds from Fig. 5 caption; original graphic viewed. — Fig. 5B–C; human fibroblast methods; Statistical Analysis

Carmofur In Vivo Studies

Carmofur at 30 mg/kg intraperitoneally every 12 hours from postnatal day 10 prolonged lifespan in Twi/FDH mice. The authors reported no lifespan benefit in Twi mice and discussed possible drug-associated toxicity, including shorter survival in some treated animals. The benefit therefore depended on the tested genotype and regimen. [3]

Genotype-dependent mouse survival response

Animal study · Twitcher mice (GALC−/−, Asah1+/+) and Twi/FDH mice (GALC−/−, Asah1+/−) [3]

Carmofur prolonged survival in Twi/FDH mice, whereas benefit was not observed in Twi mice. The authors discuss possible drug-associated toxicity and decreased lifespan in some treated Twi mice.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every 12 h
Treatment course
From postnatal day 10 for the remainder of life.
Vehicle
DMSO stock diluted with Solutol and citrate buffer; final proportions not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Twi/FDH survival
30 mg/kg
Same-genotype vehicle-treated mice.Median lifespan significantly increased versus vehicle (Fig. 5G, **P ≤ 0.01).[3]
Twi survival limitation
30 mg/kg
Same-genotype vehicle-treated mice.Discussion reports no lifespan increase and decreased lifespan in some treated Twi mice; possible drug-associated toxicity may limit efficacy.[3]
Twi/FDH survival
Model: GALC−/−, Asah1+/− mice
Reported limits: Numerical median survival and cohort size not extracted; no curve-digitized values.
Twi survival limitation
Model: GALC−/−, Asah1+/+ mice
Reported limits: Numerical median survival and cohort size not extracted; no curve-digitized values.
Methods and source locations

Compound reported in the paper: Carmofur; Compound label in the paper: Carmofur

Research findings for the reported material and model; no supplier-lot equivalence or clinical efficacy inference.

Pharmacological Results/Discussion; Fig. 5G and caption; Carmofur Administration

Twi/FDH survival · Fig. 5G and caption; pharmacological Discussion; Carmofur Administration

Twi survival limitation · Fig. 5G and caption; pharmacological Discussion; Carmofur Administration

Specifications

Manufacturer Adooq Bioscience
CAS Number 61422-45-5
Formula C11H16FN3O3
Molecular Weight 257.26
Synonyms HCFU; 1-hexylcarbamoyl-5-fluorouracil
SMILES
CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 48 mg/mL (186.58 mM)
Water Insoluble
Ethanol 9 mg/mL (34.98 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Carmofur Research References

  1. [1] Natalia Realini, Carlos Solorzano, Chiara Pagliuca, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity Scientific reports (2013). PMID: 23301156 DOI: 10.1038/srep01035 Source material
  2. [2] Alexey Dementiev, Andrzej Joachimiak, Ha Nguyen, et al. Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur Journal of medicinal chemistry (2019). PMID: 30525581 DOI: 10.1021/acs.jmedchem.8b01723 Source material
  3. [3] Yedda Li, Yue Xu, Bruno A Benitez, et al. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target Proceedings of the National Academy of Sciences of the United States of America (2019). PMID: 31527255 DOI: 10.1073/pnas.1912108116 Source material

Added to your cart

View Cart Checkout
Loading...